Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.